Featured Story | | | Thursday, August 24, 2017 Omeros has defended the data supporting its mooted rival to Soliris after STAT sought answers to questions raised by a short seller. The Seattle-based biotech used the statement to sketch out its case for OMS721 while reiterating its commitment to unmask the author of a short report. |
|
|
| This week's sponsor is FierceBiotech Drug Development Forum. | | | Save 15% on the FierceBiotech 2nd Drug Development Forum
Network with 300+ biotech leaders and 90+ executive-level speakers at the largest biotech conference for optimizing pipeline strategies, partnerships and deal making September 25-27 in Boston, MA. Sign up today & save 15% w/ code C942FIERCE. |
Top Stories Thursday, August 24, 2017 The FDA has granted priority review status to Roche’s hemophilia A candidate emicizumab, setting up the Swiss drugmaker to learn its fate by Feb. 23. Roche enters the review process armed with impressive efficacy data that risks being undermined by safety concerns and a spat with Shire. Thursday, August 24, 2017 After nearly a year and three term revisions, Accelerated Pharma is pulling its initial public offering. Thursday, August 24, 2017 Canadian investment group TRC Capital—well known for its mini-tender offer strategy—has now set its sights on Ionis, and the biotech group is not happy. Thursday, August 24, 2017 GlaxoSmithKline and Propeller Health are expanding their R&D partnership, inked in 2015, into a commercial one, under which both companies will be able to commercialize Propeller’s digital respiratory health management system for use with Glaxo’s Ellipta inhaler. Thursday, August 24, 2017 Nonclinical service-focused CRO Envigo will soon be able to access capital in the public markets, as it’s merging with publicly traded Avista Healthcare Public Acquisition Corporation. The combined company is expected to be valued at about $924 million. Thursday, August 24, 2017 AstraZeneca has pegged big hopes on its clot-fighter Brilinta, and it continues to roll out numbers designed to advance them. But with two trial failures last year, and backing for long-term use already sewn up, the company might have better luck elsewhere. | This week's sponsor is FierceBiotech. | | | FierceBiotech Executive Summit- London
Join FierceBiotech for our third annual Executive Summit in London. We'll gather the experts together to discuss innovation around R&D in the UK and look ahead to what's in store for 2018 with leaders in the field discussing trends in the industry. |
Resources Sponsored by: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Presented By: MPI Research FierceBiotech interviews Dr. DeWit to discuss a common cause for drug development delays, and strategies to avoid these costly setbacks. Sponsored by: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored by: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. 2nd Strategic Partnerships for Drug Repurposing Oct 26-27 | Boston, MA FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA FierceBiotech Executive Summit- London October 2, 2017 | London Hear from 130+ Experts Leading the Way in Life Science Marketing October 3-6, 2017 | Philadelphia, PA Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA | 